BioMarin (BMRN) legal chief sells shares and earns performance RSUs

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

BioMarin Pharmaceutical EVP and Chief Legal Officer George Eric Davis reported both stock sales and equity awards. On February 26, 2026, he completed an open-market sale of 26,061 shares of common stock at $61.36 per share, leaving 72,453 shares held directly afterward.

On February 25, 2026, he acquired three blocks of common stock through grants or awards totaling 15,224 earned restricted stock units (RSUs), all at a stated price of $0.00 per share. These RSUs were earned under performance-based awards tied to relative total shareholder return, development goals, and core operating margin for 2023–2025, and will vest on March 15, 2026 subject to continued service and certain earlier-vesting events.

Insider Trade Summary

Net Seller: 26,061 shares ($1,599,103)

Net Sell 4 txns

Insider Davis George Eric

Role EVP, Chief Legal Officer

Sold 26,061 shs ($1.60M)

Type	Security	Shares	Price	Value
Sale	Common Stock	26,061	$61.36	$1.60M
Grant/Award	Common Stock	6,177	$0.00	--
Grant/Award	Common Stock	6,675	$0.00	--
Grant/Award	Common Stock	2,372	$0.00	--

Holdings After Transaction: Common Stock — 72,453 shares (Direct)

Footnotes (1)

Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2026, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. Represents the total number of RSUs earned pursuant to a formula based on the number and nature of development goals achieved during 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Represents the total number of RSUs earned pursuant to a formula based on core operating margin over three, one-year periods spanning 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.

Form 4 Insider Transactions: What Each Field Means →

02/26/2026 - 08:31 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davis George Eric

(Last)

(First)

(Middle)

C/O BIOMARIN PHARMACEUTICAL INC.

770 LINDARO STREET

(Street)

SAN RAFAEL

94901

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [ BMRN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/25/2026⁽¹⁾		A		6,177⁽²⁾⁽³⁾	A	$0	89,467	D
Common Stock	02/25/2026⁽¹⁾		A		6,675⁽³⁾⁽⁴⁾	A	$0	96,142	D
Common Stock	02/25/2026⁽¹⁾		A		2,372⁽³⁾⁽⁵⁾	A	$0	98,514	D
Common Stock	02/26/2026		S		26,061	D	$61.36	72,453	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis.

2. Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.

3. Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2026, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events.

4. Represents the total number of RSUs earned pursuant to a formula based on the number and nature of development goals achieved during 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.

5. Represents the total number of RSUs earned pursuant to a formula based on core operating margin over three, one-year periods spanning 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.

Remarks:

	/s/ Tae Sang Yoo, Attorney-in-Fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did BioMarin (BMRN) report for George Eric Davis?

BioMarin reported that EVP and Chief Legal Officer George Eric Davis sold 26,061 common shares at $61.36 on February 26, 2026, and received three performance-based RSU grants totaling 15,224 units on February 25, 2026, all held as direct ownership.

How many BioMarin (BMRN) shares did George Eric Davis sell and at what price?

George Eric Davis sold 26,061 shares of BioMarin common stock in an open-market transaction at $61.36 per share on February 26, 2026. After this sale, he directly owned 72,453 common shares according to the reported Form 4 data.

What RSU awards did George Eric Davis earn from BioMarin (BMRN)?

On February 25, 2026, Davis earned three performance-based RSU awards totaling 15,224 units. These RSUs were granted at $0.00 per share and are convertible into common stock on a 1:1 basis under BioMarin’s 2017 Equity Incentive Plan.

What performance periods and metrics apply to the BioMarin (BMRN) RSUs?

The earned RSUs relate to performance from 2023 through 2025. Payouts are based on relative total shareholder return, the number and nature of development goals achieved, and core operating margin over three one-year periods, as defined in BioMarin’s 2017 Equity Incentive Plan.

When do George Eric Davis’s BioMarin (BMRN) RSUs vest?

Although earned, George Eric Davis’s RSUs vest on March 15, 2026, provided he continues serving with the company through that date. The awards may vest earlier upon certain specified events set out in the underlying performance-based RSU agreements.

How many BioMarin (BMRN) shares did George Eric Davis hold after the RSU grants?

After the February 25, 2026 RSU grants, Davis’s direct holdings were reported at 98,514 shares before the later sale. Following the February 26, 2026 sale of 26,061 shares, his direct ownership stood at 72,453 shares of BioMarin common stock.